Charles River Laboratories International, Inc.

NYSE:CRL Stock Report

Market Cap: US$9.5b

Charles River Laboratories International Valuation

Is CRL undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CRL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: CRL ($185.77) is trading below our estimate of fair value ($327.56)

Significantly Below Fair Value: CRL is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CRL?

Key metric: As CRL is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for CRL. This is calculated by dividing CRL's market cap by their current earnings.
What is CRL's PE Ratio?
PE Ratio23x
EarningsUS$413.08m
Market CapUS$9.50b

Price to Earnings Ratio vs Peers

How does CRL's PE Ratio compare to its peers?

The above table shows the PE ratio for CRL vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average60.2x
BRKR Bruker
28.3x15.8%US$8.6b
TECH Bio-Techne
77.2x21.2%US$11.6b
QGEN Qiagen
106.8x34.4%US$9.9b
MEDP Medpace Holdings
28.6x10.8%US$10.4b
CRL Charles River Laboratories International
23x12.1%US$9.5b

Price-To-Earnings vs Peers: CRL is good value based on its Price-To-Earnings Ratio (23x) compared to the peer average (60.2x).

Price to Earnings Ratio vs Industry

How does CRL's PE Ratio compare vs other companies in the US Life Sciences Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
REPC.F RepliCel Life Sciences
0.3xn/aUS$123.50k
No more companies available in this PE range
CRL 23.0xIndustry Avg. 36.2xNo. of Companies4PE020406080100+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: CRL is good value based on its Price-To-Earnings Ratio (23x) compared to the Global Life Sciences industry average (36.2x).

Price to Earnings Ratio vs Fair Ratio

What is CRL's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CRL PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio23x
Fair PE Ratio25.2x

Price-To-Earnings vs Fair Ratio: CRL is good value based on its Price-To-Earnings Ratio (23x) compared to the estimated Fair Price-To-Earnings Ratio (25.2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst CRL forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$185.77
US$215.22
+15.9%
12.7%US$260.00US$164.00n/a19
Dec ’25US$199.06
US$216.27
+8.6%
12.8%US$260.00US$164.00n/a19
Nov ’25US$180.96
US$209.80
+15.9%
13.9%US$260.00US$151.00n/a19
Oct ’25US$194.08
US$221.66
+14.2%
11.3%US$260.00US$175.00n/a17
Sep ’25US$197.75
US$224.07
+13.3%
10.0%US$260.00US$191.00n/a17
Aug ’25US$242.84
US$252.78
+4.1%
10.2%US$300.00US$200.00n/a17
Jul ’25US$203.24
US$261.05
+28.4%
9.0%US$300.00US$226.00n/a16
Jun ’25US$208.44
US$263.13
+26.2%
8.4%US$300.00US$226.00n/a13
May ’25US$232.69
US$270.67
+16.3%
7.7%US$300.00US$235.00n/a13
Apr ’25US$268.73
US$264.63
-1.5%
10.1%US$300.00US$200.00n/a14
Mar ’25US$264.38
US$260.34
-1.5%
8.8%US$290.00US$200.00n/a14
Feb ’25US$219.54
US$232.10
+5.7%
12.5%US$270.00US$189.00n/a15
Jan ’25US$236.40
US$224.97
-4.8%
11.9%US$270.00US$189.00n/a16
Dec ’24US$201.68
US$213.47
+5.8%
9.6%US$260.00US$189.00US$199.0616
Nov ’24US$167.52
US$234.20
+39.8%
9.1%US$275.00US$200.00US$180.9615
Oct ’24US$195.98
US$238.64
+21.8%
7.8%US$275.00US$207.00US$194.0814
Sep ’24US$209.62
US$249.57
+19.1%
7.4%US$280.00US$207.00US$197.7514
Aug ’24US$209.31
US$244.86
+17.0%
8.2%US$280.00US$205.00US$242.8414
Jul ’24US$210.25
US$248.07
+18.0%
7.8%US$280.00US$205.00US$203.2414
Jun ’24US$196.34
US$248.07
+26.3%
7.8%US$280.00US$205.00US$208.4414
May ’24US$190.10
US$252.21
+32.7%
7.8%US$290.00US$203.00US$232.6914
Apr ’24US$201.82
US$254.36
+26.0%
7.7%US$290.00US$203.00US$268.7314
Mar ’24US$222.92
US$257.57
+15.5%
6.3%US$290.00US$230.00US$264.3814
Feb ’24US$248.21
US$265.69
+7.0%
7.4%US$305.00US$233.00US$219.5413
Jan ’24US$217.90
US$268.54
+23.2%
5.5%US$300.00US$241.00US$236.4013
Dec ’23US$226.20
US$268.54
+18.7%
5.5%US$300.00US$241.00US$201.6813

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 01:49
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/28
Annual Earnings2023/12/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Charles River Laboratories International, Inc. is covered by 45 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David ToungArgus Research Company
Gregory BolanAvondale Partners
Eric ColdwellBaird